– USA, MA – ReWalk Robotics Ltd. (Nasdaq: RWLK), announced today that the Company has appointed Allen Chunlin Han to the board of directors of the Company.
Ms. Ning Cong has departed the Board as of May 14, 2019, and Mr. Han has been appointed to ReWalk Board as of May 15, 2019, pursuant to the investment agreement with Timwell Corporation Limited.
“We would like to thank Ning for her service on the ReWalk Board and are pleased to welcome Allen to our Board of Directors as a Timwell representative. We look forward to working with Allen and Timwell,” said ReWalk CEO Larry Jasinski.
About Allen Han
Mr. Han is an executive director of Liquid Harmony Limited and serves as Head of Investment and Financing for Realcan Pharmaceutical Group Co. Ltd., a large distributor of medical drugs and equipment in China with access to more than 8,000 hospitals and 33,000 primary medical institutions, where he has been instrumental in acquiring more than 50 distribution companies and participated in three joint venture investments. Mr. Han holds a Bachelor of Science degree in pharmacology from McGill University in Montreal, Canada. His father, Xu Han, and his mother, Renhua Zhang, indirectly control Timwell affiliate Realcan Ambrum Healthcare Industry Investment Partnership Enterprise, and Mr. Xu Han is the sole shareholder of Timwell.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke. ReWalk’s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany.
For more information: https://rewalk.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.